Showing results (1531-1540 of 2,287) with videos related to

Sort By:
Pageof 229
HIV Medicine|December 22, 2015
Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug managementA Rotzinger, I Locatelli, O Bugnon, et al.
HIV Medicine|August 27, 2015
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiationS Jose, K Quinn, D Dunn, et al.
HIV Medicine|January 15, 2015
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort dataJ Vingerhoets, V Calvez, P Flandre, et al.
HIV Medicine|September 8, 2015
HPV load and anal cytological abnormalitiesL B Maia, L C Marinho, M V Carneiro, et al.
HIV Medicine|September 25, 2014
The association of adiposity with kidney function decline among HIV-infected adults: findings from the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) studyA Malkina, R Scherzer, M G Shlipak, et al.
HIV Medicine|September 13, 2014
Autoantibodies binding to ubiquitin-fold modifier-conjugating enzyme 1 (Ufc1) and pleckstrin homology domain containing, family G (with RhoGef domain) member 2 (Plekhg2) are associated with mycobacterial infectionsA Tellermann, T Witte, C Lansche, et al.
HIV Medicine|September 19, 2014
Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapyJ R Koethe, C A Jenkins, M Turner, et al.
HIV Medicine|September 20, 2014
Routine CD4 cell count monitoring seldom contributes to clinical decision-making on antiretroviral therapy in virologically suppressed HIV-infected patientsE P F Chow, T R H Read, M Y Chen, et al.
HIV Medicine|March 31, 2016
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapyL Calza, V Colangeli, E Magistrelli, et al.
HIV Medicine|April 20, 2016
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral loadP Flandre, P Pugliese, C Allavena, et al.
Pageof 229